Compare GE Aerospace (GE) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Aerospace vs Natera Inc. Common Stock — how do they compare? GE Aerospace trades at $307.25 (market cap $318.55B), while Natera Inc. Common Stock trades at $392.78 (market cap $57.03B). The key difference: GE Aerospace is far larger — about 5.6× Natera Inc. Common Stock's market cap, and GE Aerospace pays a 0.61% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold GE Aerospace for 111 Days and Natera Inc. Common Stock for 0 Days on average.
| GE | NTRA | |
|---|---|---|
Market Cap | $318.55B | $57.03B |
Volume | 3,302,020 | 1,131,157 |
Sector | Industrials | Health |
52-Week High | $381.22 | $425.64 |
52-Week Low | $273.25 | $179.42 |
Typical Hold Time | 111 Days | 0 Days |
Enterprise Value | $328.36B | $56.18B |
Dividend Yield | 0.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Aerospace trades at $307.63, down 0.33% with a bearish technical signal despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, achieving 48.79% ROE and 17.72% net margins. Recent news highlights a $12 billion acquisition of Consolidated Precision Products to address supply chain bottlenecks, while analysts maintain a strong buy consensus with a $409.60 price target representing 33% upside potential.
GE presents a compelling investment case with robust earnings momentum and strategic acquisitions, though technical weakness and high valuation multiples (P/E 36.28) warrant caution. The stock faces near-term pressure from cost concerns and regulatory scrutiny of the CPP deal, but strong defense demand and shareholder returns support long-term growth prospects.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
